试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-28
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
编号:NCT04908956登记状态:提前终止企业 / 申办者:ETOP IBCSG Partners Foundation
药物 / 成分:Osimertinib、Stereotactic Body Radiation Therapy (SBRT)
登记的停止原因(原文):The trial struggled with low activation due to the COVID pandemic. The Steering Committee took the decision to close the accrual in the STEREO trial as of 31 October 2023. It is important to note that no safety concerns have led to this decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-28
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
编号:NCT05000450登记状态:提前终止企业 / 申办者:Allogene Therapeutics
药物 / 成分:ALLO-605、ALLO-647、Fludarabine、Cyclophosphamide
登记的停止原因(原文):Terminated (Halted Prematurely)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-27
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
编号:NCT00330564登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:SU011248
登记的停止原因(原文):Slow accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-27
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
编号:NCT04313881登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Magrolimab、Azacitidine、Placebo
登记的停止原因(原文):Study discontinued due to futility based on a planned analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-27
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
编号:NCT04893018登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Efineptakin alfa
登记的停止原因(原文):Terminated due to end of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-27
PET Imaging of Cyclooxygenase in Multiple Sclerosis
编号:NCT05062083登记状态:提前终止企业 / 申办者:National Institute of Mental Health (NIMH)
药物 / 成分:11C-MC1、11C-PS13、Ketoprofen、Celecoxib
登记的停止原因(原文):due to futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-27
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
编号:NCT06217146登记状态:提前终止企业 / 申办者:M. H MediCane Ltd.
药物 / 成分:Medical Cannabis、Placebo Oil
登记的停止原因(原文):Part I: Open-label was completed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-26
Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
编号:NCT00875004登记状态:提前终止企业 / 申办者:Institut du Cancer de Montpellier - Val d'Aurelle
药物 / 成分:epoetin beta、systemic chemotherapy、quality-of-life assessment
登记的停止原因(原文):After two years of trial initiation, only 27 out of 300 patients were included. During this period, the international recommendations for the use of COOL were modified.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-26
Advanced Gastrointestinal Endoscopic Imaging
编号:NCT01034670登记状态:提前终止企业 / 申办者:Stanford University
药物 / 成分:Dual axis endoscopic microscope、wide field fluorescence system、CellVizio、fluorescent Peptide
登记的停止原因(原文):Change in personnel and cessation of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-26
Efficacy of Ginseng for Patients on Regorafenib
编号:NCT02581059登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Regorafenib、Ginseng
登记的停止原因(原文):Funder terminated.
查看官方原始记录 ↗